Clinical trial
A Phase 2, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study to Determine the Safety and Efficacy of Oral SDX in Patients With Idiopathic Hypersomnia (IH)
NCT05668754 is registered in ClinicalTrials.gov with Zevra Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study to Determine the Safety and Efficacy of Oral SDX in Patients With Idiopathic Hypersomnia (IH)
- Lead sponsor
- Zevra Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 28, 2022
- Completion date
- March 21, 2024
- Enrollment
- 66 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.